242 related articles for article (PubMed ID: 28398017)
1. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
De Vecchis R; Cesaro A; Ariano C
Minerva Cardioangiol; 2018 Oct; 66(5):659-670. PubMed ID: 28398017
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
De Vecchis R; Cesaro A; Ariano C; Giasi A; Cioppa C
J Clin Med Res; 2017 Jun; 9(6):488-498. PubMed ID: 28496549
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Vecchis R; Cesaro A; Ariano C
Interv Med Appl Sci; 2017 Sep; 9(3):123-135. PubMed ID: 29201436
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
DE Vecchis R; Ariano C
Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Chen Z; Zhao K; Xiao C; He Z; Liu S; Wu X; Shi S; Guo Y
Saudi Pharm J; 2022 Aug; 30(8):1079-1087. PubMed ID: 36164567
[TBL] [Abstract][Full Text] [Related]
8. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
Jiang R; Wang L; Zhu CT; Yuan P; Pudasaini B; Zhao QH; Gong SG; He J; Liu JM; Hu QH
Hypertens Res; 2015 Dec; 38(12):829-39. PubMed ID: 26202179
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
[TBL] [Abstract][Full Text] [Related]
11. Ventricular-Arterial Coupling and Exercise-Induced Pulmonary Hypertension During Low-Level Exercise in Heart Failure With Preserved or Reduced Ejection Fraction.
Obokata M; Nagata Y; Kado Y; Kurabayashi M; Otsuji Y; Takeuchi M
J Card Fail; 2017 Mar; 23(3):216-220. PubMed ID: 27737768
[TBL] [Abstract][Full Text] [Related]
12. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
[TBL] [Abstract][Full Text] [Related]
13. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
14. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
15. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
[TBL] [Abstract][Full Text] [Related]
16. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
[TBL] [Abstract][Full Text] [Related]
17. Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials.
De Vecchis R; Ariano C
Cardiovasc Diagn Ther; 2017 Jun; 7(3):272-287. PubMed ID: 28567353
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis.
Teramoto K; Santos M; Claggett B; John JE; Solomon SD; Kitzman D; Folsom AR; Cushman M; Matsushita K; Skali H; Shah AM
PLoS Med; 2020 Oct; 17(10):e1003361. PubMed ID: 33057391
[TBL] [Abstract][Full Text] [Related]
19. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.
Zhuang XD; Long M; Li F; Hu X; Liao XX; Du ZM
Int J Cardiol; 2014 Apr; 172(3):581-7. PubMed ID: 24534379
[TBL] [Abstract][Full Text] [Related]
20. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
